Apollo Hospitals Enterprise Ltd
Date 10.02.2025
Apollo Hospitals Enterprise
Timeframe : Day Chart
Remarks
Technical :
1 Price has retraced till neckline of right-angled ascending broadening wedge
2 Same is the area where 200 EMA is also extending support at neckline
3 Same is the strong support/resistance band
3 Previous rounding cup neckline is also the same overlapping mentioned above zones
4 Hence, 6750-6650 is most important zone as trend shifter in the stock.
Fundamental :
Today on 10.02.2025 company declared quarterly results
Q3 CONS NET PROFIT 3.72B RUPEES VS 2.45B (YOY)
Q3 REVENUE 55.27B RUPEES VS 48.5B (YOY)
Q3 EBITDA 7.62B RUPEES VS 6.13B (YOY)
Q3 EBITDA MARGIN 13.78% VS 12.65% (YOY)
CO DECLARED AN INTERIM DIVIDEND OF RS 9 PER SHARE
OVERALL GOOD PERFORMANCE
COMPANY HIGHLIGHTS
MARKET CAP ₹ 97,277 Cr II STOCK P/E 82.2 (HIGH)
BOOK VALUE ₹ 522 II ROCE 15.1 %
ROE 13.3 %
Regards,
Ankur
Apollo Hospitals Enterprise
Timeframe : Day Chart
Remarks
Technical :
1 Price has retraced till neckline of right-angled ascending broadening wedge
2 Same is the area where 200 EMA is also extending support at neckline
3 Same is the strong support/resistance band
3 Previous rounding cup neckline is also the same overlapping mentioned above zones
4 Hence, 6750-6650 is most important zone as trend shifter in the stock.
Fundamental :
Today on 10.02.2025 company declared quarterly results
Q3 CONS NET PROFIT 3.72B RUPEES VS 2.45B (YOY)
Q3 REVENUE 55.27B RUPEES VS 48.5B (YOY)
Q3 EBITDA 7.62B RUPEES VS 6.13B (YOY)
Q3 EBITDA MARGIN 13.78% VS 12.65% (YOY)
CO DECLARED AN INTERIM DIVIDEND OF RS 9 PER SHARE
OVERALL GOOD PERFORMANCE
COMPANY HIGHLIGHTS
MARKET CAP ₹ 97,277 Cr II STOCK P/E 82.2 (HIGH)
BOOK VALUE ₹ 522 II ROCE 15.1 %
ROE 13.3 %
Regards,
Ankur
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.